OPTIMUM CLINICAL RESEARCH INC. ETHICS REVIEW BOARD 604 TAUNTON ROAD WEST, OSHAWA, ONTARIO L1L 0N9

PLEASE COMPLETE THIS FORM, AND Email to: info@optimumerb.ca

* 2023 SITE QUESTIONNAIRE*

Please complete this questionnaire *in its entirety* and return to Optimum. A completed questionnaire will be kept on file for each site, for each protocol. *Unless otherwise indicated*, the information that you fill in below will appear on the front of your final stamped consent form that you will receive from Optimum.

<u>PLEASE PRINT CLEARLY</u> – <u>DO NOT LEAVE BLANKS</u>

If print is not clear, this may result in a delay.

Name of Clinic/Site	Name:	
Address:		
City:	Province	Postal Code
Main Tel #	Fax #	
Name of Principal In	nvestigator(s)	
Name of Co-Investi	gator(s)	
Co-Investigator(s) A	Address(es) (if different from PI Addr	ress)
Study Coordinator(s	r communication from Optimum (v	
PROTOCOL INFO	ORMATION:	
SPONSOR:		
	BER (or other identifying information	•
1) How long ha	us your site been conducting clinical r	research?
2) Approximate	Approximately how many research studies has your site conducted in the last year?	

Version: January 1, 2023

3)	Has your site and/or the investigator been audited by a governmental regulatory authority?	
	□ Yes □ No If yes, when did this audit occur?	
	What was the outcome of this audit?	
4)	Describe your facility (attach a brochure, if available): □ Hospital □ Public Health Clinic □ Private Clinic □ Other: (please describe):	
5)	How close is your site to a hospital with emergency facilities?	
6)	Do you have emergency facilities available on-site in the case of an emergency? (Ie. Crash cart, etc.) □ Yes □ No	
7)	Are there any community attitudes in terms of religious, ethical, ethnic, or economic attitudes which will affect the conduct of any research at your site? Yes No If yes, please describe:	
8)	If you enroll non-English speaking subjects, do you use a translated consent form? □ Yes □ No	
	If yes, into what other language(s) will you require the forms for this study to be translated?	
	Do you have someone at your site who is capable of explaining the study and answering questions in the language of the non-English speaking subject? \Box Yes \Box No	
9)	Have you ever had a subject seek compensation for injury as a result of their participation in a clinical research study? \Box Yes \Box No	
	If yes, were there problems resolving it?	
10)	Have you submitted this protocol to another ethics board prior to this submission? ☐ Yes ☐ No If yes, please attach details of the other Board's findings and outcome of the submission.	
	Information to be inserted into your site-specific consent form (please note: if you require slated consent forms, you must also include the clearly printed or typed translation of any tional wording used):	
a) Co	ontact Information for Subjects for Study-related Questions	
Name	eTel:	
b) Co	ontact Information for Subjects in case of an emergency/adverse event (if different from (a))	
Name	eTel:	

Version: January 1, 2023

Page 2 of 3 2023 Site Questionnaire

c) COMPENSATION FOR PARTICIPATION: To consent form: (Please choose one of the 4 options)	his information will be inserted into your site-specific
	ted expenses. If be no costs to you as a result of your participation in ocket study-related expenses, such as parking, taxi,
	ll be no costs to you as a result of your participation in unt offor each study visit, to cover study-
☐ I will not compensate subjects. (Addition to Consent Form will be: " <i>There w participation in this study</i> ."	vill be no costs to you as a result of your
☐ I will compensate subjects and would lik (Insert your preferred wording) Addition to C	·
***Please note: if you require transla printed or typed translation of the p	nted consent forms, you must also include the clearly roposed wording to be used:
(Attach an additional sheet if necessary. This vector) prior to insertion)	wording will be reviewed by the Board (or by the
PLEASE ENSURE THAT ALL OF THE ABOVE QUACCURATELY.	JESTIONS ARE ANSWERED FULLY AND
research or the consent form without prior approval by	cipated problems involving risks to research subjects whom I am responsible. No changes will be made to the the Ethics Review Board. The information in this Site ator or someone under the Investigator's supervision will abjects before obtaining their signed informed consent.
Principal Investigator Signature (or designee)	Date
Printed Name of Principal Investigator (or designee)	

2023 Site Questionnaire

Version: January 1, 2023

Page 3 of 3